Sympathetic nervous system dysfunction in multiple sclerosis, linking Neurodegeneration to a reduced response to therapy

Current Pharmaceutical Design

Volumn 18, Issue 12, 2012, Pages 1635-1644

  Sternberg, Zohara ^a  

^a JACOBS NEUROLOGICAL INSTITUTE   (United States)

Author keywords

Antidepressants; Antihypertensive; Antiplatelets; Autonomic dysfunction; Benzodiazepines; Multiple sclerosis; Noradrenergic receptors; Spasticity; Statins

Indexed keywords

ACETYLSALICYLIC ACID; ADRENERGIC RECEPTOR; ANTICONVULSIVE AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; ATENOLOL; ATORVASTATIN; BACLOFEN; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BETA INTERFERON; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ESZOPICLONE; GABAPENTIN; GLATIRAMER; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOMODULATING AGENT; MEVINOLIN; MITOXANTRONE; NORADRENALIN; PERINDOPRIL; PREGABALIN; PROPRANOLOL; SALBUTAMOL; SIMVASTATIN; TIZANIDINE; UNINDEXED DRUG; ZOLPIDEM TARTRATE;

ADRENERGIC SYSTEM; ALGORITHM; ARTICLE; CHRONIC DRUG ADMINISTRATION; DEPRESSION; DISEASE COURSE; DOWN REGULATION; FATIGUE; GENDER; HUMAN; IMMUNOMODULATION; INFLAMMATION; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NONHUMAN; NORADRENALIN BLOOD LEVEL; OSTEOPOROSIS; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; SIDE EFFECT; TH1 TH2 BALANCE; TREATMENT RESPONSE;

ALGORITHMS; ANIMALS; DRUG INTERACTIONS; HUMANS; IMMUNOMODULATION; MULTIPLE SCLEROSIS; NEURODEGENERATIVE DISEASES; SYMPATHETIC NERVOUS SYSTEM;

EID: 84860204193     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212799958639     Document Type: Article

References (128)

1. Joyner MJ, Charkoudian N, Wallin BG. A sympathetic view of the sympathetic nervous system and human blood pressure regulation. Exp Physiol 2008; 93: 715-724.
2. Elenkov IJ, Wilder RL, Chrousos GP, Vizi ES. The sympathetic nerve an integrative interface between two supersystems: the brain and the immune system. Pharmacol Rev 2000; 52: 595-638.
3. Bennett JL, Stuve O. Update on inflammation, neurodegeneration, and immunoregulation in multiple sclerosis: therapeutic implications. Clin Neuropharmacol 2009; 32: 121-132.
4. Crane IJ, Forrester JV. Th1 and Th2 lymphocytes in autoimmune disease. Crit Rev Immunol 2005; 25: 75-102.
5. Owens T. The enigma of multiple sclerosis: inflammation and neurodegeneration cause heterogeneous dysfunction and damage. Curr Opin Neurol 2003; 16: 259-265.
6. Sanders VM, Straub RH. Norepinephrine, the beta-adrenergic receptor, and immunity. Brain Behav Immun 2002; 16: 290-332.
7. Harrison DG, Gongora MC. Oxidative stress and hypertension. Med Clin North Am 2009; 93: 621-635.
8. Hasko G, Elenkov IJ, Kvetan V, Vizi ES. Differential effect of selective block of alpha 2-adrenoreceptors on plasma levels of tumour necrosis factor-alpha, interleukin-6 and corticosterone induced by bacterial lipopolysaccharide in mice. J Endocrinol 1995; 144: 457-462.
9. Lorton D, Lubahn C, Bellinger DL. Potential use of drugs that target neural-immune pathways in the treatment of rheumatoid arthritis and other autoimmune diseases. Curr Drug Targets Inflamm Allergy 2003; 2: 1-30.
10. Szelenyi J, Kiss JP, Vizi ES. Differential involvement of sympathetic nervous system and immune system in the modulation of TNF-alpha production by alpha2- and beta-adrenoceptors in mice. J Neuroimmunol 2000; 103: 34-40.
11. Flachenecker P. Autonomic dysfunction in Guillain-Barre syndrome and multiple sclerosis. J Neurol 2007; 254 Suppl 2: 1101-1196.
12. Flachenecker P, Reiners K, Krauser M, Wolf A, Toyka KV. Autonomic dysfunction in multiple sclerosis is related to disease activity and progression of disability. Mult Scler 2001; 7: 327-34.
13. Leussink VI, Mäurer M, Toyka KV, Rieckmann PPF. Autonomic dysregulation in patients with clinically isolated syndrome. In: eds., ECTRIMS 2003 Annual Meeting. Multiple Sclerosis: Milan, It, 2003; pp. S91.
14. Saari A, Tolonen U, Paakko E, Suominen K, Pyhtinen J, Sotaniemi KA et al. Sympathetic skin responses in multiple sclerosis. Acta Neurol Scand 2008; 118: 226-231.
15. Sternberg Z, Leung C, Sternberg D, LI F, Hojnacki D, Karmon Y, et al. The prevalence of cardiovascular risk factors in multiple sclerosis patients. (Submitted to the journal of "CNS & Neurological Disorders-Drug Targets", 2011).
16. Cryer PE. The barrier of hypoglycemia in diabetes. Diabetes 2008; 57: 3169-3176.
17. Rajda C, Bencsik K, Vecsei LL, Bergquist J. Catecholamine levels in peripheral blood lymphocytes from multiple sclerosis patients. J Neuroimmunol 2002; 124: 93-100.
18. Karaszewski JW, Reder AT, Anlar B, Kim WC, Arnason BG. Increased lymphocyte beta-adrenergic receptor density in progressive multiple sclerosis is specific for the CD8+, CD28-suppressor cell. Ann Neurol 1991; 30: 42-47.
19. Shetty DN, Pathak SS. Correlation between plasma neurotransmitters and memory loss in pregnancy. J Reprod Med 2002; 47: 494-496.
20. Aune B, Vartun A, Oian P, Sager G. Evidence of dysfunctional beta2-adrenoceptor signal system in pre-eclampsia. BJOG 2000; 107: 116-121.
21. Tschada R, Hettenbach A, Melchert F, Alken P. Pregnancy-induced changes in adrenergic receptors. Z Geburtshilfe Perinatol 1991; 195: 182-186.
22. Zoukos Y, Leonard JP, Thomaides T, Thompson AJ, Cuzner ML. beta-Adrenergic receptor density and function of peripheral blood mononuclear cells are increased in multiple sclerosis: a regulatory role for cortisol and interleukin-1. Ann Neurol 1992; 31: 657-662.
23. Zoukos Y, Thomaides TN, Kidd D, Cuzner ML, Thompson A. Expression of beta2 adrenoreceptors on peripheral blood mononuclear cells in patients with primary and secondary progressive multiple sclerosis: a longitudinal six month study. J Neurol Neurosurg Psychiatry 2003; 74: 197-202.
24. Zoukos Y, Kidd D, Woodroofe MN, Kendall BE, Thompson AJ, Cuzner ML. Increased expression of high affinity IL-2 receptors and beta-adrenoceptors on peripheral blood mononuclear cells is associated with clinical and MRI activity in multiple sclerosis. Brain 1994; 117 (Pt 2): 307-315.
25. Giorelli M, Livrea P, Trojano M. Post-receptorial mechanisms underlie functional disregulation of beta2-adrenergic receptors in lymphocytes from Multiple Sclerosis patients. J Neuroimmunol 2004; 155: 143-149.
26. Harper SJ, Wilkie N. MAPKs: new targets for neurodegeneration. Expert Opin Ther Targets 2003; 7: 187-200.
27. Arnsten AF, Goldman-Rakic PS. Alpha 2-adrenergic mechanisms in prefrontal cortex associated with cognitive decline in aged nonhuman primates. Science 1985; 230: 1273-1276.
28. Zarrindast MR, Khodjastehfar E, Oryan S, Torkaman-Boutorabi A. Baclofen-impairment of memory retention in rats: possible interaction with adrenoceptor mechanism(s). Eur J Pharmacol 2001; 411: 283-288.
29. Wiegmann K, Muthyala S, Kim DH, Arnason BG, Chelmicka-Schorr E. Beta-adrenergic agonists suppress chronic/relapsing experimental allergic encephalomyelitis (CREAE) in Lewis rats. J Neuroimmunol 1995; 56: 201-206.
30. Dinter H, Tse J, Halks-Miller M, Asarnow D, Onuffer J et al. The type IV phosphodiesterase specific inhibitor mesopram inhibits experimental autoimmune encephalomyelitis in rodents. J Neuroimmunol 2000; 108: 136-146.
31. Chelmicka-Schorr E, Kwasniewski MN, Wollmann RL. Sympathectomy augments adoptively transferred experimental allergic encephalomyelitis. J Neuroimmunol 1992; 37: 99-103.
32. Simonini MV, Polak PE, Sharp A, McGuire S, Galea E, Feinstein DL. Increasing CNS noradrenaline reduces EAE severity. J Neuroimmune Pharmacol 2010; 5: 252-259.
33. Hashioka S, Klegeris A, Monji A, Kato T, Sawada M, McGeer PL et al. Antidepressants inhibit interferon-gamma-induced microglial production of IL-6 and nitric oxide. Exp Neurol 2007; 206: 33-42.
34. Russo-Neustadt A, Beard RC, Cotman CW. Exercise, antide-pressant medications, and enhanced brain derived neurotrophic factor expression. Neuropsychopharmacology 1999; 21: 679-682.
35. Berne-Fromell K, Fromell H, Lundkvist S, Lundkvist P. Is multiple sclerosis the equivalent of Parkinson's disease for noradrenaline? Med Hypotheses 1987; 23: 409-415.
36. Puri BK, Bydder GM, Chaudhuri KR, Al Saffar BY, Curati WL, White SJ et al. MRI changes in multiple sclerosis following treatment with lofepramine and L-phenylalanine. Neuroreport 2001; 12: 1821-1824.
37. Matsumoto T, Ogata M, Koga K, Shigematsu A. Effect of peripheral benzodiazepine receptor ligands on lipopolysaccharide-induced tumor necrosis factor activity in thioglycolate-treated mice. Antimicrob Agents Chemother 1994; 38: 812-816.
38. Sternberg Z, Leung C, Sternberg D, LI F, Hojnacki D, Munschauer F. The Effects of cardiovascular drugs on the course of multiple sclerosis. (In preparation for submission). 2011.
39. Krakauer M, Sorensen PS, Khademi M, Olsson T, Sellebjerg F. Dynamic T-lymphocyte chemokine receptor expression induced by interferon-beta therapy in multiple sclerosis. Scand J Immunol 2006; 64: 155-163.
40. Schrempf W, Ziemssen T. Glatiramer acetate: mechanisms of action in multiple sclerosis. Autoimmun Rev 2007; 6: 469-475.
41. Sanders VM, Baker RA, Ramer-Quinn DS, Kasprowicz DJ, Fuchs BA, Street NE. Differential expression of the beta2-adrenergic receptor by Th1 and Th2 clones: implications for cytokine production and B cell help. J Immunol 1997; 158: 4200-4210.
42. Goebel MU, Baase J, Pithan V, Exton M, Saller B, Schedlowski M et al. Acute interferon beta-1b administration alters hypothalamic-pituitary-adrenal axis activity, plasma cytokines and leukocyte distribution in healthy subjects. Psychoneuroendocrinology 2002; 27: 881-892.
43. Goebel MU, Hubell D, Kou W, Janssen OE, Katsarava Z, Limmroth V et al. Behavioral conditioning with interferon beta-1a in humans. Physiol Behav 2005; 84: 807-814.
44. Zaffaroni M, Marino F, Bombelli R, Rasini E, Monti M, Ferrari M et al. Therapy with interferon-beta modulates endogenous catecholamines in lymphocytes of patients with multiple sclerosis. Exp Neurol 2008; 214: 315-321.
45. Hamamcioglu K, Reder AT. Interferon-beta regulates cytokines and BDNF: greater effect in relapsing than in progressive multiple sclerosis. Mult Scler 2007; 13: 459-470.
46. Rajda C, Bencsik K, Fuvesi J, Seres E, Vecsei L, Bergquist J. The norepinephrine level is decreased in the lymphocytes of long-term interferon-beta-treated multiple sclerosis patients. Mult Scler 2006; 12: 265-270.
47. Cosentino M, Zaffaroni M, Marino F, Bombelli R, Ferrari M, Rasini E et al. Catecholamine production and tyrosine hydroxylase expression in peripheral blood mononuclear cells from multiple sclerosis patients: effect of cell stimulation and possible relevance for activation-induced apoptosis. J Neuroimmunol 2002; 133: 233-240.
48. Panitch H, Miller A, Paty D, Weinshenker B. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 2004; 63: 1788-1795.
49. Tanuma N, Sakuma H, Sasaki A, Matsumoto Y. Chemokine expression by astrocytes plays a role in microglia/macrophage activation and subsequent neurodegeneration in secondary progressive multiple sclerosis. Acta Neuropathol 2006; 112: 195-204.
50. Sorensen TL, Sellebjerg F. Distinct chemokine receptor and cytokine expression profile in secondary progressive MS. Neurology 2001; 57: 1371-1376.
51. Esposito F, Radaelli M, Martinelli V, Sormani MP, Martinelli Boneschi F, Moiola L et al. Comparative study of mitoxantrone efficacy profile in patients with relapsing-remitting and secondary progressive multiple sclerosis. Mult Scler 2010; 16: 1490-1499.
52. Vogelgesang A, Rosenberg S, Skrzipek S, Broker BM, Dressel A. Mitoxantrone treatment in multiple sclerosis induces TH2-type cytokines. Acta Neurol Scand 2010; 122: 237-243.
53. Zeinstra E, Wilczak N, De Keyser J. [3H]dihydroalprenolol binding to beta adrenergic receptors in multiple sclerosis brain. Neurosci Lett 2000; 289: 75-77.
54. Laureys G, Clinckers R, Gerlo S, Spooren A, Wilczak N, Kooijman R et al. Astrocytic beta(2)-adrenergic receptors: from physiology to pathology. Prog Neurobiol 2010; 91: 189-199.
55. Khoury SJ, Healy BC, Kivisakk P, Viglietta V, Egorova S, Guttmann CR et al. A randomized controlled double-masked trial of albuterol add-on therapy in patients with multiple sclerosis. Arch Neurol 2010; 67: 1055-1061.
56. Smith SM, Vale WW. The role of the hypothalamic-pituitary-adrenal axis in neuroendocrine responses to stress. Dialogues Clin Neurosci 2006; 8: 383-95.
57. Rink L, Cakman I, Kirchner H. Altered cytokine production in the elderly. Mech Ageing Dev 1998; 102: 199-209.
58. Collins KJ. Age-related changes in autonomic control: the use of beta blockers in the treatment of hypertension. Cardiovasc Drugs Ther 1991; 4 Suppl 6: 1257-1262.
59. Leray E, Yaouanq J, Le Page E, Coustans M, Laplaud D, Oger J et al. Evidence for a two-stage disability progression in multiple sclerosis. Brain 2010; 133: 1900-1913.
60. Hinojosa-Laborde C, Chapa I, Lange D, Haywood JR. Gender differences in sympathetic nervous system regulation. Clin Exp Pharmacol Physiol 1999; 26: 122-126.
61. Hakamada-Taguchi R, Uehara Y, Kuribayashi K, Numabe A, Saito K, Negoro H et al. Inhibition of hydroxymethylglutaryl-coenzyme a reductase reduces Th1 development and promotes Th2 development. Circ Res 2003; 93: 948-956.
62. Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med 2000; 6: 1399-1402.
63. Zamvil SS, Steinman L. Cholesterol-lowering statins possess anti-inflammatory activity that might be useful for treatment of MS. Neurology 2002; 59: 970-971.
64. Szramka M, Harriss L, Ninnio D, Windebank E, Brack J, Skiba M et al. The effect of rapid lipid lowering with atorvastatin on autonomic parameters in patients with coronary artery disease. Int J Cardiol 2007; 117: 287-291.
65. Sena A, Pedrosa R, Graca Morais M. Therapeutic potential of lovastatin in multiple sclerosis. J Neurol 2003; 250: 754-755.
66. Vollmer T, Key L, Durkalski V, Tyor W, Corboy J, Markovic-Plese S et al. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 2004; 363: 1607-1608.
67. Birnbaum G, Cree B, Altafullah I, Zinser M, Reder AT. Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis. Neurology 2008; 71: 1390-1395.
68. Sakuma T, Morimoto S, Aota Y, Takahashi N, Toyoda N, Kosaki A et al. Efficacy of clonidine in patients with essential hypertension with neurovascular contact of the rostral ventrolateral medulla. Hypertens Res 2010; 33: 633-637.
69. Gage JR, Fonarow G, Hamilton M, Widawski M, Martinez-Maza O, Vredevoe DL. Beta blocker and angiotensin-converting enzyme inhibitor therapy is associated with decreased Th1/Th2 cytokine ratios and inflammatory cytokine production in patients with chronic heart failure. Neuroimmunomodulation 2004; 11: 173-180.
70. Liu X, Zhu X, Wang A, Fan H, Yuan H. Effects of angiotensin-II receptor blockers on experimental autoimmune myocarditis. Int J Cardiol 2009; 137: 282-288.
71. Zarrindast MR, Haidari H, Jafari MR, Djahanguiri B. Influence of beta-adrenoceptor agonists and antagonists on baclofen-induced memory impairment in mice. Behav Pharmacol 2004; 15: 293-297.
72. Eguchi K, Kario K, Shimada K. Differential effects of a long-acting angiotensin converting enzyme inhibitor (temocapril) and a long-acting calcium antagonist (amlodipine) on ventricular ectopic beats in older hypertensive patients. Hypertens Res 2002; 25: 329-333.
73. Savignac M, Gomes B, Gallard A, Narbonnet S, Moreau M, Leclerc C et al. Dihydropyridine receptors are selective markers of Th2 cells and can be targeted to prevent Th2-dependent immunopathological disorders. J Immunol 2004; 172: 5206-5212.
74. Starklint J, Bech JN, Pedersen EB. Urinary excretion of aquaporin-2 after furosemide and felodipine in healthy humans. Scand J Clin Lab Invest 2005; 65: 249-261.
75. Namazi MR. The addition of diuretics to corticosteroids with high mineralocorticoid activity may lead to the better control of humoral autoimmune disorders. Int Immunopharmacol 2004; 4: 325.
76. Del Rio G, Verlardo A, Zizzo G, Marrama P, Della Casa L. Sex differences in catecholamine response to clonidine. Int J Obes Relat Metab Disord 1993; 17: 465-469.
77. Freedman RR, Girgis R. Effects of menstrual cycle and race on peripheral vascular alpha-adrenergic responsiveness. Hypertension 2000; 35: 795-799.
78. Roussel V, Yi F, Jauberteau MO, Couderq C, Lacombe C, Michelet V et al. Prevalence and clinical significance of anti-phospholipid antibodies in multiple sclerosis: a study of 89 patients. J Autoimmun 2000; 14: 259-25.
79. Snoep JD, Hovens MM, Pasha SM, Frolich M, Pijl H, Tamsma JT et al. Time-dependent effects of low-dose aspirin on plasma renin activity, aldosterone, cortisol, and catecholamines. Hypertension 2009; 54: 1136-1142.
80. Hermida RC, Fernandez JR, Ayala DE, Iglesias M, Halberg F. Time-dependent effects of ASA administration on blood pressure in healthy subjects. Chronobiologia 1994; 21: 201-213.
81. Marcinkiewicz J, Radziszewski W, Chain BM. Prostaglandin E2 (PGE2) differentially regulates the production of IL-2 and IL-3 by murine immune T-cells. Folia Histochem Cytobiol 1992; 30: 1-4.
82. Zhuang HP, Li J, Liu LH. Effect of aspirin combined with perindopril on prostacyclin, thromboxone A2, and norepinephrine in the blood of arteriosclerosis rabbit models and the cardiac function. Hunan Yi Ke Da Xue Xue Bao 2003; 28: 37-40.
83. Taniyama K, Niwa M, Kataoka Y, Yamashita K. Inhibition of the vesicular release of neurotransmitters by stimulation of GABAB receptor. Ann N Y Acad Sci 1993; 707: 496-499.
84. Suzdak PD, Gianutsos G. Differential coupling of GABA-A and GABA-B receptors to the noradrenergic system. J Neural Transm, 1985; 62: 77-89.
85. Navarro CE, Cabrera RJ, Donoso AO. Interaction between glutamate and GABA on 3H-noradrenaline release from rat hypothalamus. Brain Res Bull 1995; 37: 119-122.
86. Sandyk R, Gillman MA. Baclofen-induced memory impairment. Clin Neuropharmacol, 1985; 8: 294-295.
87. Duthey B, Hubner A, Diehl S, Boehncke S, Pfeffer J, Boehncke WH. Anti-inflammatory effects of the GABA(B) receptor agonist baclofen in allergic contact dermatitis. Exp Dermatol 2010; 19: 661-666.
88. Da Settimo F, Taliani S, Trincavelli ML, Montali M, Martini C. GABA A/Bz receptor subtypes as targets for selective drugs. Curr Med Chem 2007; 14: 2680-701.
89. Bateson AN. The benzodiazepine site of the GABAA receptor: an old target with new potential? Sleep Med 2004; 5 Suppl 1: S9-S15.
90. Kubota T, Hirota K, Yoshida H, Takahashi S, Anzawa N, Ohkawa H et al. Effects of sedatives on noradrenaline release from the medial prefrontal cortex in rats. Psychopharmacology (Berl) 1999; 146: 335-338.
91. Yoshimura R, Ueda N, Hori H, Ikenouchi-Sugita A, Umene-Nakano W, Nakamura J. Different patterns of longitudinal changes in plasma levels of catecholamine metabolites and brain-derived neurotrophic factor after administration of atypical antipsychotics in first episode untreated schizophrenic patients. World J Biol Psychiatry 2010;11: 256-261.
92. Suzuki H, Yamadera H, Asayama K, Kudo Y, Ito T, Tamura Y et al. Study of nocturnal sleep and the carryover effects of triazolam and brotizolam using neurophysiological and subjective methods. Neuropsychobiology 2003; 47: 158-164.
93. Rudolph U, Crestani F, Benke D, Brunig I, Benson JA, Fritschy JM et al. Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes. Nature 1999; 401: 796-800.
94. Papadopoulos V, Baraldi M, Guilarte TR, Knudsen TB, Lacapere JJ, Lindemann P et al. Translocator protein (18kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol Sci 2006; 27: 402-409.
95. Wang JK, Morgan JI, Spector S. Benzodiazepines that bind at peripheral sites inhibit cell proliferation. Proc Natl Acad Sci U S A 1984; 81: 753-756.
96. File SE, Green AR, Nutt DJ, Vincent ND. On the convulsant action of Ro 5-4864 and the existence of a micromolar benzodiazepine binding site in rat brain. Psychopharmacology (Berl) 1984; 82: 199-202.
97. Zavala F. Benzodiazepines, anxiety and immunity. Pharmacol Ther 1997; 75: 199-216.
98. Zavala F, Taupin V, Descamps-Latscha B. In vivo treatment with benzodiazepines inhibits murine phagocyte oxidative metabolism and production of interleukin 1, tumor necrosis factor and interleukin-6. J Pharmacol Exp Ther 1990; 255: 442-450.
99. Wei M, Li L, Meng R, Fan Y, Liu Y, Tao L et al. Suppressive effect of diazepam on IFN-gamma production by human T cells. Int Immunopharmacol; 10: 267-271.
100. Banati RB, Egensperger R, Maassen A, Hager G, Kreutzberg GW, Graeber MB. Mitochondria in activated microglia in vitro. J Neurocytol 2004; 33: 535-541.
101. Mattner F, Katsifis A, Staykova M, Ballantyne P, Willenborg DO. Evaluation of a radiolabelled peripheral benzodiazepine receptor ligand in the central nervous system inflammation of experimental autoimmune encephalomyelitis: a possible probe for imaging multiple sclerosis. Eur J Nucl Med Mol Imaging 2005; 32: 557-563.
102. Basile AS, Skolnick P. Tissue specific regulation of peripheral-type benzodiazepine receptor density after chemical sympathectomy. Life Sci 1988; 42: 273-283.
103. Caldiroli E, Marino F, Cosentino M, De Ponti F, Fietta AM, Mazzone A et al. Peripheral benzodiazepine receptor expression on leukocytes and neutrophil function during anticonvulsant monotherapy. Pharmacology 1998; 57: 215-221.
104. Brawek B, Loffler M, Dooley DJ, Weyerbrock A, Feuerstein TJ. Differential modulation of K(+)-evoked (3)H-neurotransmitter release from human neocortex by gabapentin and pregabalin. Naunyn Schmiedebergs Arch Pharmacol 2008; 376: 301-307.
105. Taylor CP, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res 2007; 73: 137-150.
106. Taylor CP, Gee NS, Su TZ, Kocsis JD, Welty DF, Brown JP et al. A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res 1998; 29: 233-249.
107. Nader ND, Ignatowski TA, Kurek CJ, Knight PR, Spengler RN. Clonidine suppresses plasma and cerebrospinal fluid concentrations of TNF-alpha during the perioperative period. Anesth Analg 2001; 93: 363-369, 3rd contents page.
108. Nance PW. Alpha adrenergic and serotonergic agents in the treatment of spastic hypertonia. Phys Med Rehabil Clin N Am 2001; 12: 889-905.
109. Dawood T, Schlaich M, Brown A, Lambert G. Depression and blood pressure control: All antidepressants are not the same. Hypertension 2009; 54: e1; author reply e2.
110. Vollmar P, Nessler S, Kalluri SR, Hartung HP, Hemmer B. The antidepressant venlafaxine ameliorates murine experimental autoimmune encephalomyelitis by suppression of pro-inflammatory cytokines. Int J Neuropsychopharmacol 2009; 12: 525-536.
111. Song C, Halbreich U, Han C, Leonard BE, Luo H. Imbalance between pro- and anti-inflammatory cytokines, and between Th1 and Th2 cytokines in depressed patients: the effect of electroacupuncture or fluoxetine treatment. Pharmacopsychiatry 2009; 42: 182-188.
112. Srivastava N, Barthwal MK, Dalal PK, Agarwal AK, Nag D, Seth PK et al. A study on nitric oxide, beta-adrenergic receptors and antioxidant status in the polymorphonuclear leukocytes from the patients of depression. J Affect Disord 2002; 72: 45-52.
113. Mann JJ, Brown RP, Halper JP, Sweeney JA, Kocsis JH, Stokes PE et al. Reduced sensitivity of lymphocyte beta-adrenergic receptors in patients with endogenous depression and psychomotor agitation. N Engl J Med 1985; 313: 715-720.
114. Hwang J, Zheng LT, Ock J, Lee MG, Kim SH, Lee HW et al. Inhibition of glial inflammatory activation and neurotoxicity by tricyclic antidepressants. Neuropharmacology 2008; 55: 826-834.
115. Dredge K, Connor TJ, Kelly JP, Leonard BE. Differential effect of a single high dose of the tricyclic antidepressant imipramine on interleukin-1beta and tumor necrosis factor-alpha secretion following an in vivo lipopolysaccharide challenge in rats. Int J Immunopharmacol 1999; 21: 663-673.
116. Taler M, Gil-Ad I, Lomnitski L, Korov I, Baharav E, Bar M et al. Immunomodulatory effect of selective serotonin reuptake inhibitors (SSRIs) on human T lymphocyte function and gene expression. Eur Neuropsychopharmacol 2007; 17: 774-780.
117. Guillemin GJ, Kerr SJ, Pemberton LA, Smith DG, Smythe GA, Armati PJ et al. IFN-beta1b induces kynurenine pathway metabolism in human macrophages: potential implications for multiple sclerosis treatment. J Interferon Cytokine Res 2001; 21: 1097-1101.
118. Brown JN, Howard CA, Kemp DW. Modafinil for the treatment of multiple sclerosis-related fatigue. Ann Pharmacother 2010; 44: 1098-1103.
119. de Saint Hilaire Z, Orosco M, Rouch C, Blanc G, Nicolaidis S. Variations in extracellular monoamines in the prefrontal cortex and medial hypothalamus after modafinil administration: a microdialysis study in rats. Neuroreport 2001; 12: 3533-3537.
120. Stone EA, Cotecchia S, Lin Y, Quartermain D. Role of brain alpha 1B-adrenoceptors in modafinil-induced behavioral activity. Synapse 2002; 46: 269-270.
121. Minzenberg MJ, Carter CS. Modafinil: a review of neurochemical actions and effects on cognition. Neuropsychopharmacology 2008; 33: 1477-1502.
122. Berridge CW. Noradrenergic modulation of arousal. Brain Res Rev 2008; 58: 1-17.
123. Flachenecker P, Rufer A, Bihler I, Hippel C, Reiners K, Toyka KV et al. Fatigue in MS is related to sympathetic vasomotor dysfunction. Neurology 2003; 61: 851-853.
124. Takeuchi T, Tsuboi T, Arai M, Togari A. Adrenergic stimulation of osteoclastogenesis mediated by expression of osteoclast differentiation factor in MC3T3-E1 osteoblast-like cells. Biochem Pharmacol 2001; 61: 579-586.
125. Berris KK, Repp AL, Kleerekoper M. Glucocorticoid-induced osteoporosis. Curr Opin Endocrinol Diabetes Obes 2007; 14: 446-450.
126. Togari A. Adrenergic regulation of bone metabolism: possible involvement of sympathetic innervation of osteoblastic and osteoclastic cells. Microsc Res Tech 2002; 58: 77-84.
127. Eskandari F, Martinez PE, Torvik S, Phillips TM, Sternberg EM, Mistry S et al. Low bone mass in premenopausal women with depression. Arch Intern Med 2007; 167: 2329-2336.
128. D'Amelio P, Grimaldi A, Di Bella S, Tamone C, Brianza SZ, Ravazzoli MG et al. Risedronate reduces osteoclast precursors and cytokine production in postmenopausal osteoporotic women. J Bone Miner Res 2008; 23: 373-379.